Dupilumab leads to rapid, sustained improvements in erythrodermic atopic dermatitis

Treatment with dupilumab is safe and effective, resulting in rapid and sustained improvements in the signs of erythrodermic atopic dermatitis (AD), according to a post hoc analysis of 6 randomized clinical trials.

In this analysis, 209 patients with erythrodermic AD ≥ 90% body surface area (BSA) and Global Individual Sign Score for erythema of ≥ 1 at baseline received dupilumab once weekly or every 2 weeks, or placebo, either as monotherapy or with concomitant topical corticosteroids (TCS).

Compared to placebo, patients treated with dupilumab once weekly and every 2 weeks either as monotherapy or with TCS had significant improvements in the percentage of BSA affected by AD, Eczema Area and Severity Index score, and Peak Pruritus Numerical Rating Scale score. Biomarker levels were also significantly reduced.

With monotherapy, nominally statistically significant improvements in Eczema Area and Severity Index and Peak Pruritus Numerical Rating Scale scores were seen as early as week 1.

In patients treated with dupilumab the most frequent adverse events were injection-site reaction, conjunctivitis, and nasopharyngitis.

Reference
Paller AS, Silverberg JI, Cork MJ, et al. Efficacy and Safety of Dupilumab in Patients With Erythrodermic Atopic Dermatitis: A Post Hoc Analysis of 6 Randomized Clinical Trials. JAMA Dermatol. Published online February 01, 2023. doi:10.1001/jamadermatol.2022.6192